- Home
- ADSK vs ZTS Comparison
ADSK vs ZTS Comparison
Compare ADSK & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSK
- ZTS
- Stock Information
- Founded
- ADSK 1982
- ZTS 1952
- Country
- ADSK United States
- ZTS United States
- Employees
- ADSK N/A
- ZTS N/A
- Industry
- ADSK Computer Software: Prepackaged Software
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- ADSK Technology
- ZTS Health Care
- Exchange
- ADSK Nasdaq
- ZTS Nasdaq
- Market Cap
- ADSK 63.8B
- ZTS 66.2B
- IPO Year
- ADSK N/A
- ZTS 2013
- Fundamental
- Price
- ADSK $310.93
- ZTS $143.56
- Analyst Decision
- ADSK Buy
- ZTS Buy
- Analyst Count
- ADSK 25
- ZTS 8
- Target Price
- ADSK $358.20
- ZTS $200.25
- AVG Volume (30 Days)
- ADSK 1.4M
- ZTS 3.1M
- Earning Date
- ADSK 11-25-2025
- ZTS 11-04-2025
- Dividend Yield
- ADSK N/A
- ZTS 1.39%
- EPS Growth
- ADSK N/A
- ZTS 14.10
- EPS
- ADSK 4.81
- ZTS 5.82
- Revenue
- ADSK $6,605,000,000.00
- ZTS $9,385,000,000.00
- Revenue This Year
- ADSK $17.53
- ZTS $3.90
- Revenue Next Year
- ADSK $11.28
- ZTS $5.92
- P/E Ratio
- ADSK $64.73
- ZTS $24.67
- Revenue Growth
- ADSK 13.78
- ZTS 5.27
- 52 Week Low
- ADSK $232.67
- ZTS $139.34
- 52 Week High
- ADSK $329.09
- ZTS $196.55
- Technical
- Relative Strength Index (RSI)
- ADSK 47.02
- ZTS 38.26
- Support Level
- ADSK $309.57
- ZTS $142.15
- Resistance Level
- ADSK $326.18
- ZTS $148.79
- Average True Range (ATR)
- ADSK 5.89
- ZTS 2.77
- MACD
- ADSK -1.70
- ZTS 0.06
- Stochastic Oscillator
- ADSK 26.28
- ZTS 38.25
About ADSK Autodesk Inc.
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction; product design and manufacturing; and media and entertainment. Autodesk software enables design, modeling, and rendering needs of these industries. The company has over 4 million paid subscribers across 180 countries.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.